US4447415A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Plasma-free medium for platelet storage
Assignee: Individual
•
Filing: 1982-12-14
•
Granted: 1984-05-08
•
Expires: 2002-12-14
Abstract
Abstract Blood platelet concentrate in a plasma-free medium. Method for storage of blood platelets in a plasma-free medium which comprises centrifuging plasma to obtain a platelet pellet, removing the supernatant plasma, and resuspending the platelet pellet in a balanced salt medium. The balanced salt medium is an isotonic solution and may be selected from well known physiologically tolerable salt mediums. Additives to enhance platelet storage can be added to the salt medium.
Inventors
- 👤 Gail A. Rock
- 👤 George A. Adams
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 15:31
CPC Classifications
A; A01; A01N; A01N1/00; A01N1/10; A01N1/12; A01N1/122; A01N1/126; A61; A61K; A61K35/00; A61K35/12; A61K35/14; A61K35/19
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
97 words
A method for the preparation of a blood platelet concentrate for administration to animals which comprises centrifuging plasma to obtain a platelet pellet, removing the supernatant plasma, and resuspending the platelet pellet in a medium consisting essentially of: a balanced, physiologically compatible, saline solution; an anticoagulant; and one or more additives to enhance stability of the platelets selected from (a) nutrients to improve the storage life of the platelets, (b) reversible inhibitors for platelet activation, (c) substances to raise cyclic adenosine monophosphate levels which have reversible effects on platelets, and (d) buffering agents which are physiologically compatible.
Claim 2
Independent Claim
97 words
A method for the preparation of a blood platelet concentrate for administration to animals which comprises centrifuging plasma to obtain a platelet pellet, removing the supernatant plasma, and resuspending the platelet pellet in a medium consisting essentially of: a balanced, physiologically compatible, saline solution; an anticoagulant; and one or more additives to enhance stability of the platelets selected from (a) nutrients to improve the storage life of the platelets, (b) reversible inhibitors for platelet activation, (c) substances to raise cyclic adenosine monophosphate levels which have reversible effects on platelets, and (d) buffering agents which are physiologically compatible.
Claim 3
Dependent Claim
18 words
A method as claimed in claim 1 wherein the nutrients are selected from fructose, adenine or acetyl CoA.
Claim 4
Dependent Claim
22 words
A method as claimed in claim 1 wherein the reversible inhibitors for platelet activation are selected from indomethacin, quinacrine or vitamin E.
Claim 5
Dependent Claim
29 words
A method as claimed in claim 1 wherein the substances to raise cyclic adenosine monophosphate levels are selected from prostaglandins E 1 , D 2 or I 2 .
Claim 6
Dependent Claim
18 words
A method as claimed in claim 1 wherein the buffering agents are selected from phosphate or amino acids.
Claim 7
Dependent Claim
20 words
A method as claimed in claim 5 wherein the amino acids are selected from histidine, cysteine, tyrosine, lysine or arginine.
Claim 8
Dependent Claim
43 words
A method as claimed in claim 1 wherein the balanced salt medium is selected from Spinner salt solution, Tyrode's solution, Seligmann's balanced salt solution, Earle's balanced salt solutions, Dulbecco's phosphate buffered saline, Hank's balanced salt solutions, Gey's balanced salt solutions or Puck's saline.
Claim 9
Dependent Claim
16 words
A method as claimed in claim 1 wherein the balanced salt medium is a Tyrode's solution.
Claim 10
Dependent Claim
19 words
A method as claimed in claim 6 wherein the Tyrode's solution contains a phosphate buffer or a histidine buffer.
Claim 11
Dependent Claim
28 words
A method as claimed in claim 6 wherein extraction and a washing step is used to remove plasma from platelets prior to final suspension in the Tyrode's solution.
Claim 12
Dependent Claim
25 words
A method as claimed in claim 7 wherein extraction is used to remove plasma from platelets prior to final suspension in the modified Tyrode's solution.
Claim 13
Dependent Claim
13 words
A method as claimed in claim 1 wherein the plasma is human plasma.
Claim 14
Dependent Claim
20 words
A method as claimed in claim 1 wherein the plasma is derived from freshly collected whole blood or by apheresis.
Claim 15
Dependent Claim
25 words
A method as claimed in claim 1 wherein the plasma is derived from freshly collected whole human blood or by apheresis on a human donor.
Claim 16
Dependent Claim
13 words
A method as claimed in claim 1 wherein the plasma is human plasma.
Claim 17
Dependent Claim
20 words
A method as claimed in claim 1 wherein the plasma is derived from freshly collected whole blood or by apheresis.
Claim 18
Dependent Claim
25 words
A method as claimed in claim 1 wherein the plasma is derived from freshly collected whole human blood or by apheresis on a human donor.
Claim 19
Dependent Claim
77 words
A platelet concentrate composition for administration to animals comprising blood platelets suspended in a medium consisting essentially of: a balanced, physiologically compatible, saline solution; an anticoagulant; and one or more additives to enhance stability of the platelets selected from (a) nutrients to improve the storage life of the platelets, (b) reversible inhibitors for platelet activation, (c) substances to raise cyclic adenosine monophosphate levels which have reversible effects on platelets, and (d) buffering agents which are physiologically compatible.
Claim 20
Dependent Claim
77 words
A platelet concentrate composition for administration to animals comprising blood platelets suspended in a medium consisting essentially of: a balanced, physiologically compatible, saline solution; an anticoagulant; and one or more additives to enhance stability of the platelets selected from (a) nutrients to improve the storage life of the platelets, (b) reversible inhibitors for platelet activation, (c) substances to raise cyclic adenosine monophosphate levels which have reversible effects on platelets, and (d) buffering agents which are physiologically compatible.
Claim 21
Dependent Claim
19 words
A platelet concentrate as claimed in claim 18 wherein the nutrients are selected from fructose, adenine or acetyl CoA.
Claim 22
Dependent Claim
23 words
A platelet concentrate as claimed in claim 18 wherein the reversible inhibitors for platelet activation are selected from indomethacin, quinacrine or vitamin E.
Claim 23
Dependent Claim
30 words
A platelet concentrate as claimed in claim 18 wherein the substances to raise cyclic adenosine monophosphate levels are selected from prostaglandins E 1 , D 2 or I 2 .
Claim 24
Dependent Claim
19 words
A platelet concentrate as claimed in claim 18 wherein the buffering agents are selected from phosphate or amino acids.
Claim 25
Dependent Claim
21 words
A platelet concentrate as claimed in claim 22, wherein the amino acids are selected from histidine, cysteine, tyrosine, lysine or arginine.
Claim 26
Dependent Claim
44 words
A platelet concentrate as claimed in claim 18, wherein the balanced salt medium is selected from Spinner salt solution, Tyrode's solution, Seligmann balanced salt solution, Earle's balanced salt solutions, Dulbecco's phosphate buffered saline, Hank's balanced salt solutions, Gey's balanced salt solutions or Puck's saline.
Claim 27
Dependent Claim
17 words
A platelet concentrate as claimed in claim 18 wherein the balanced salt medium is a Tyrode's solution.
Claim 28
Dependent Claim
20 words
A platelet concentrate as claimed in claim 25 wherein the Tyrode's solution contains a phosphate buffer or a histidine buffer.
Claim 29
Dependent Claim
14 words
A platelet concentrate as claimed in claim 18 wherein the plasma is human plasma.
Claim 30
Dependent Claim
26 words
A platelet concentrate as claimed in claim 18 wherein the human plasma is derived from freshly collected whole blood or by apheresis on a human donor.
References Cited (Backward Citations)
US2786014A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-05-08 | 1987-11-07 | 1988-05-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-05-08 | 1991-11-07 | 1992-05-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-05-08 | 1995-11-07 | 1996-05-08 | $7700.00 | Window Closed / Lapsed |